Natco Pharma Limited · NSE:NATCOPHARM
Natco Pharma — Investor Presentation (February 2016)
20 slides from Natco Pharma's investor presentation, February 2016
Slide 1: Natco Pharma Limited
Natco Pharma Limited Feb 2016 Strictly Private and Confidential
Slide 2: Important Disclosure
Important Disclosure This presentation has been prepared by Natco Pharma Limited (the “Company”) solely for information purposes without regard to any specific objectives, financial situations or informational needs of any particular person. This presentation should not be construed as legal, tax, i
Slide 3: Natco Pharma at a Glance
Natco Pharma at a Glance Vertically integrated pharmaceutical company with focus on niche therapeutic areas and complex products in Finished Dosage Formulations (“FDF”) and Active Pharmaceutical Ingredients (“APIs”) Diversified business model with presence across segments including Domestic & In
Slide 4: Company Evolution
Company Evolution 1986: Inaugurated 2003: Launched Oncology division Parentals with introduction of flagship brand 2009: Inaugurated NATCO Organics 2014: Incorporated Natco Pharma Manufacturing facility VEENAT (generic Imatinib Mesylate) at Chennai, India, with facilities Australia Pty at Nagarjunas
Slide 5: Key Business Segments
Key Business Segments Formulations API Others (Domestic & Exports) International Domestic Portfolio of niche and complex Leading Player1 in India’s Filed 31 DMFs in US with Operates one pharmacy store products for US generic oncology space led by over 15 products under in US flagship brands
Slide 6: Key Growth Pillars in Place Supported by a Strong Foundation for Value Creation
Key Growth Pillars in Place Supported by a Strong Foundation for Value Creation Expanding US footprint through a Emerging Leading Position Pillars of differentiated Presence in in Domestic Growth product pipeline of Europe, Asia and Oncology Market niche and complex RoW Markets products De-risked bu
Slide 7: Expanding US Footprint Through a Differentiated Product Pipeline of Niche and Complex Products
Expanding US Footprint Through a Differentiated Product Pipeline of Niche and Complex Products Pipeline of niche and complex generics products in US 38 ANDA filings including 16 Para IV filings with USFDA (as on December 31, 2015) targeting a combined market of over US$15.0bn^ 16 approved ANDA
Slide 8: Expanding US Footprint Through a Differentiated Product Pipeline (Cont'd)
Expanding US Footprint Through a Differentiated Product Pipeline of Niche and Complex Products (Cont’d) Overview of Key Filings Therapeutic Segment / Key Brand Molecule Dosage Form Para IV Para III Market Size (US$mn)# Indication Copaxone 20&40mg Glatiramer 20&40mg Multiple Sclerosis PFS 4,318 Gle
Slide 9: De-risked Business Model through Partnership with Global Pharmaceutical Players
De-risked Business Model through Partnership with Global Pharmaceutical Players Mitigation Strategy Adopted and successfully implemented partnership strategy for international formulations product ─ Has product specific partnerships with global generic players at different stages of a potential AN
Slide 10: Leading Position in Domestic Oncology Segment
Leading Position in Domestic Oncology Segment Focus on oncology segment in domestic market and hold leading Oncology Revenue - Gross (INRmn) market share in operated portfolio of product 1,947 Entered the segment with launch of Veenat (Imatinib generic version) in 2003 1,547 1,403 1,322 1,236
Slide 11: Leading Position In Domestic Oncology Segment (Cont'd)
Leading Position In Domestic Oncology Segment (Cont’d) Supportive Care Zoldonat Glioma (Zoledronic Acid) Temonat (Temozolomide) Lymphoma Breast Cancer Bendit Fulvenat (Fulvestrant) (Bendamustine) Leukemia Xtane (Exemestane) Veenat (Imatinib) Letronet (Letrozole) Lung Cancer Geftinat (Geftinib) HCC/R
Slide 12: Expanding Presence in Domestic Specialty Pharma Segment
Expanding Presence in Domestic Specialty Pharma Segment Domestic Specialty Pharma Hepatitis C Opportunity Portfolio of 13 products catering Launched generic Sovaldi and its combinations for the treatment of Hepatitis C primarily to Gastroenterology, in India & Nepal under its brand HEPCINAT & HE
Slide 13: Expanding Europe & RoW Presence
Expanding Europe & RoW Presence RoW formulation growth to be driven by launches in EU, scale up in Latin America and Canada and phased launch of generic Sovaldi Europe Sell our products in UK and Germany 4 approvals Distribution arrangements with our business partner Canada Asia Pacific (Inclu
Slide 14: Strong In-House API Development with Vertical Integration for Key Formulation Products
Strong In-House API Development with Vertical Integration for Key Formulation Products Gross API Revenue (INRmn) Strategically important business – develops APIs primarily for captive consumption of its FDF portfolio as well as third party sales 2,571 2,221 Portfolio of 31 USDMFs with over 15 pr
Slide 15: Strong Research & Development Capabilities
Strong Research & Development Capabilities Strong R&D capabilities demonstrated by its complex and niche product filings in formulations and API segments 16 ANDAs Approved Two well equipped research facilities with capabilities across synthetic chemistry, (including 3 tentative approvals) biotech
Slide 16: Commitment to Manufacturing Excellence with a Culture of Quality and Compliance
Commitment to Manufacturing Excellence with a Culture of Quality and Compliance Formulations Manufacturing Facilities Kothur Facility Nagarjuna Sagar Facility Dehradun Unit 6 Facility Dehradun Unit 7 Facility Guwahati Facility Capability: Tablets, Capsules, Capability: Ampoules, Vials, Capabil
Slide 17: Experienced Management
Experienced Management Mr. V.C Nannapaneni Holds Masters degree in Pharmaceutical Administration from the Long Island University, US Chairman and Director Over 42 years of experience in the Pharmaceutical Industry Mr. Rajeev Nannapaneni Holds bachelors degree in Quantitative Economics and Hist
Slide 18: Demonstrated Track Record of Topline and Earnings Growth
Demonstrated Track Record of Topline and Earnings Growth Total Revenue (INRmn) EBITDA (INRmn) and EBITDA Margin (%) 20.5% 22.2% 22.4% 26.0% 25.4% 8,402 7,556 2,131 6,729 1,960 5,329 1,507 4,651 1,185 952 FY2011 FY2012 FY2013 FY2014 FY2015 FY2011 FY2012 FY2013 FY2014 FY2015 PAT (INRmn) and PAT Margin
Slide 19: Historical Financials
Historical Financials Consolidated Profit & Loss Statement (INRMn) Consolidated Balance Sheet (INRMn) Particulars 31-Mar-13 31-Mar-14 31-Mar-15 Particulars 31-Mar-13 31-Mar-14 31-Mar-15 6,681 7,447 8,382 Share Capital 314 331 332 Revenue from operations (gross) Reserves and Surplus 5,022 6,928 8,128
Slide 20: Historical Financials (contd.)
Historical Financials (contd.) Consolidated Cash Flow Statement (INRMn) Q1-Q2-Q3 FY16 Consolidated Financial Results (INRMn) 31-Mar-13 31-Mar-14 31-Mar-15 31-Dec-15 30-Sep-15 30-Jun-15 Profit Before Tax 1,023 1,290 1,342 Total Revenues 2,814 2,370 2,255 Add: Depreciation and 221 304 473 Amortization